Identification

Name
Ethinyl Estradiol
Accession Number
DB00977  (APRD00691)
Type
Small Molecule
Groups
Approved
Description

A semisynthetic alkylated estradiol with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally and is often used as the estrogenic component in oral contraceptives. Ethinyl estradiol is marketed mostly as a combination oral contraceptive under several brand names such as Alesse, Tri-Cyclen, Triphasil, and Yasmin. The FDA label includes a black box warning that states that combination oral contraceptives should not be used in women over 35 years old who smoke due to the increased risk of serious cardiovascular side effects.

Structure
Thumb
Synonyms
  • 17-ethinyl-3,17-estradiol
  • 17-ethinyl-3,17-oestradiol
  • 17-ethinylestradiol
  • 17alpha-Ethinyl estradiol
  • 17α-ethynylestradiol
  • Ethinylestradiol
  • Ethinylestradiolum
  • Ethinyloestradiol
  • Ethynyl estradiol
  • Etinilestradiol
External IDs
NSC-10973
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Estinyl Tab 0.05mgTablet.05 mgOralSchering Plough1951-12-312000-07-11Canada
Estinyl Tab 0.5mgTablet.5 mgOralSchering Plough1951-12-312000-07-11Canada
Estinyl Tablets 0.02 Mg.Tablet.02 mgOralSchering Plough1951-12-311998-11-17Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
JolessaKitTeva2003-10-13Not applicableUs0555 912320170913 5456 rktojs
Larin 1.5/30KitNorth Star Rx Llc2014-03-20Not applicableUs
Larin 1/20KitNorth Star Rx Llc2013-12-04Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AfirmelleEthinyl Estradiol + LevonorgestrelKitAurobindo Pharma2016-11-14Not applicableUs
Alesse 21Ethinyl Estradiol (20 mcg) + Levonorgestrel (100 mcg)TabletOralPfizer1998-01-07Not applicableCanada
Alesse 28Ethinyl Estradiol (20 mcg) + Levonorgestrel (100 mcg)TabletOralPfizer1998-01-07Not applicableCanada
AltaveraEthinyl Estradiol + LevonorgestrelKitXiromed, Llc.2018-01-01Not applicableUs
AltaveraEthinyl Estradiol + LevonorgestrelKitSandoz2010-08-03Not applicableUs
Alyacen 1/35Ethinyl Estradiol + NorethisteroneKitRemedy Repack2018-05-16Not applicableUs
Alyacen 1/35Ethinyl Estradiol + NorethisteroneKitGlenmark Pharmaceuticals Inc.,Usa2012-01-19Not applicableUs
Alyacen 1/35Ethinyl Estradiol + NorethisteroneKitA S Medication Solutions2012-01-192017-06-20Us
Alyacen 7/7/7Ethinyl Estradiol + NorethisteroneKitA S Medication Solutions2012-01-192017-06-20Us
Alyacen 7/7/7Ethinyl Estradiol + NorethisteroneKitGlenmark Pharmaceuticals Inc.,Usa2012-01-19Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
FalessaEthinyl Estradiol + LevonorgestrelKitAvion Pharmaceuticals, Llc2014-02-17Not applicableUs
International/Other Brands
Estinyl (Schering)
Categories
UNII
423D2T571U
CAS number
57-63-6
Weight
Average: 296.4034
Monoisotopic: 296.177630012
Chemical Formula
C20H24O2
InChI Key
BFPYWIDHMRZLRN-SLHNCBLASA-N
InChI
InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1
IUPAC Name
(1S,10R,11S,14R,15S)-14-ethynyl-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2(7),3,5-triene-5,14-diol
SMILES
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3

Pharmacology

Indication

For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.

Associated Conditions
Associated Therapies
Pharmacodynamics

Ethinyl estradiol is a synthetic derivative of the natural estrogen estradiol. It is one of two estrogens currently used in oral contraceptive pills. The other, mestranol, is converted to ethinyl estradiol before it is biologically active. Ethinyl estradiol and norethindrone are used together as an oral contraceptive agent.

Mechanism of action

Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. This cascade is initiated by initially binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).

TargetActionsOrganism
AEstrogen receptor alpha
agonist
Human
UNuclear receptor subfamily 1 group I member 2
agonist
Human
USex hormone-binding globulinNot AvailableHuman
Absorption

Rapid and complete absorption follows oral intake of ethinyl estradiol (bioavailability 43%).

Volume of distribution
Not Available
Protein binding

97%

Metabolism

Hepatic. Quantitatively, the major metabolic pathway for ethinyl estradiol, both in rats and in humans, is aromatic hydroxylation, as it is for the natural estrogens.

Route of elimination
Not Available
Half life

36 +/- 13 hours

Clearance
Not Available
Toxicity

Oral, mouse LD50: 1737 mg/kg. Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females. The FDA label includes a black box warning that states that combination oral contraceptives with ethinyl estradiol should not be used in women over 35 years old who smoke due to the increased risk of serious cardiovascular side effects.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinEthinyl Estradiol may decrease the anticoagulant activities of (R)-warfarin.Experimental
(S)-WarfarinEthinyl Estradiol may decrease the anticoagulant activities of (S)-Warfarin.Experimental, Investigational
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Ethinyl Estradiol.Investigational
3-isobutyl-1-methyl-7H-xanthineThe serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be increased when it is combined with Ethinyl Estradiol.Experimental
4-hydroxycoumarinEthinyl Estradiol may decrease the anticoagulant activities of 4-hydroxycoumarin.Experimental
6-O-benzylguanineThe serum concentration of 6-O-benzylguanine can be increased when it is combined with Ethinyl Estradiol.Investigational
7-DeazaguanineThe serum concentration of 7-Deazaguanine can be increased when it is combined with Ethinyl Estradiol.Experimental
7,9-DimethylguanineThe serum concentration of 7,9-Dimethylguanine can be increased when it is combined with Ethinyl Estradiol.Experimental
8-azaguanineThe serum concentration of 8-azaguanine can be increased when it is combined with Ethinyl Estradiol.Experimental
8-chlorotheophyllineThe serum concentration of 8-chlorotheophylline can be increased when it is combined with Ethinyl Estradiol.Approved
9-DeazaguanineThe serum concentration of 9-Deazaguanine can be increased when it is combined with Ethinyl Estradiol.Experimental
9-MethylguanineThe serum concentration of 9-Methylguanine can be increased when it is combined with Ethinyl Estradiol.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
AbciximabEthinyl Estradiol may decrease the anticoagulant activities of Abciximab.Approved
AbemaciclibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Abemaciclib.Approved, Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
AceclofenacAceclofenac may increase the thrombogenic activities of Ethinyl Estradiol.Approved, Investigational
AcefyllineThe serum concentration of Acefylline can be increased when it is combined with Ethinyl Estradiol.Experimental
AcenocoumarolEthinyl Estradiol may decrease the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Ethinyl Estradiol.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational, Withdrawn
Acetylsalicylic acidEthinyl Estradiol may decrease the anticoagulant activities of Acetylsalicylic acid.Approved, Vet Approved
AcitretinThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Acitretin.Approved
AcyclovirThe serum concentration of Acyclovir can be increased when it is combined with Ethinyl Estradiol.Approved
AdapaleneThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Adapalene.Approved
AfatinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Afatinib.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Ethinyl Estradiol.Experimental, Investigational
AlbendazoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Albendazole.Approved, Vet Approved
AlbiglutideThe therapeutic efficacy of Albiglutide can be decreased when used in combination with Ethinyl Estradiol.Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Ethinyl Estradiol.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Ethinyl Estradiol.Experimental, Investigational
AlectinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Alectinib.Approved, Investigational
AlitretinoinThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Alitretinoin.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Ethinyl Estradiol.Approved
AlteplaseEthinyl Estradiol may decrease the anticoagulant activities of Alteplase.Approved
AlvocidibThe serum concentration of Alvocidib can be decreased when it is combined with Ethinyl Estradiol.Experimental, Investigational
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Ethinyl Estradiol.Approved
AmediplaseEthinyl Estradiol may decrease the anticoagulant activities of Amediplase.Investigational
AMG-222The therapeutic efficacy of AMG-222 can be decreased when used in combination with Ethinyl Estradiol.Investigational
AmiodaroneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Ethinyl Estradiol.Approved
AmlodipineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Amoxapine.Approved
AmprenavirThe metabolism of Ethinyl Estradiol can be decreased when combined with Amprenavir.Approved, Investigational
AmsacrineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Amsacrine.Approved, Investigational
AnagliptinThe therapeutic efficacy of Anagliptin can be decreased when used in combination with Ethinyl Estradiol.Investigational
AnagrelideEthinyl Estradiol may decrease the anticoagulant activities of Anagrelide.Approved
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
AncrodEthinyl Estradiol may decrease the anticoagulant activities of Ancrod.Approved, Investigational
AnistreplaseEthinyl Estradiol may decrease the anticoagulant activities of Anistreplase.Approved
AnnamycinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Annamycin.Investigational
Anthrax immune globulin humanEthinyl Estradiol may increase the thrombogenic activities of Anthrax immune globulin human.Approved
Antithrombin III humanEthinyl Estradiol may decrease the anticoagulant activities of Antithrombin III human.Approved
ApalutamideThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanEthinyl Estradiol may decrease the anticoagulant activities of Apixaban.Approved
AprepitantThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Aprepitant.Approved, Investigational
ArdeparinEthinyl Estradiol may decrease the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanEthinyl Estradiol may decrease the anticoagulant activities of Argatroban.Approved, Investigational
ArmodafinilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Armodafinil.Approved, Investigational
ArtemetherThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Artemether.Approved
Ascorbic acidThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ascorbic acid.Approved, Nutraceutical
AstaxanthinEthinyl Estradiol may decrease the anticoagulant activities of Astaxanthin.Investigational
AstemizoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Asunaprevir.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Ethinyl Estradiol can be decreased when combined with Atazanavir.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Ethinyl Estradiol.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
AzathioprineThe serum concentration of Azathioprine can be increased when it is combined with Ethinyl Estradiol.Approved
AzelastineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Azithromycin.Approved
Bafilomycin A1The serum concentration of Ethinyl Estradiol can be increased when it is combined with Bafilomycin A1.Experimental
Bafilomycin B1The serum concentration of Ethinyl Estradiol can be increased when it is combined with Bafilomycin B1.Experimental
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Ethinyl Estradiol.Investigational
BamifyllineThe serum concentration of Bamifylline can be increased when it is combined with Ethinyl Estradiol.Experimental
BarbexacloneThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Barbexaclone.Experimental
BarbitalThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Barbital.Illicit
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
BelinostatThe serum concentration of Belinostat can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
BemiparinEthinyl Estradiol may decrease the anticoagulant activities of Bemiparin.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Ethinyl Estradiol.Investigational
BenfluorexThe therapeutic efficacy of Benfluorex can be decreased when used in combination with Ethinyl Estradiol.Investigational, Withdrawn
BenzquinamideThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Benzquinamide.Withdrawn
Benzyl alcoholThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Bepridil.Approved, Withdrawn
BeraprostEthinyl Estradiol may decrease the anticoagulant activities of Beraprost.Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
BexaroteneThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Bexarotene.Approved, Investigational
BicalutamideThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Bicalutamide.Approved
BictegravirThe serum concentration of Bictegravir can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
BinimetinibThe serum concentration of Binimetinib can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
Biricodar dicitrateThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Biricodar dicitrate.Investigational
BivalirudinEthinyl Estradiol may decrease the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BosentanThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Bosentan.Approved, Investigational
Brefeldin AThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Brefeldin A.Experimental
BrinaseEthinyl Estradiol may decrease the anticoagulant activities of Brinase.Experimental
BromfenacBromfenac may increase the thrombogenic activities of Ethinyl Estradiol.Approved
BromocriptineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Bromocriptine.Approved, Investigational
BromotheophyllineThe serum concentration of Bromotheophylline can be increased when it is combined with Ethinyl Estradiol.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Ethinyl Estradiol.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Ethinyl Estradiol.Investigational, Withdrawn
BufyllineThe serum concentration of Bufylline can be increased when it is combined with Ethinyl Estradiol.Experimental
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Ethinyl Estradiol.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Cabazitaxel.Approved
CafedrineThe serum concentration of Cafedrine can be increased when it is combined with Ethinyl Estradiol.Investigational
CaffeineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Canagliflozin.Approved
CangrelorEthinyl Estradiol may decrease the anticoagulant activities of Cangrelor.Approved
Capromab pendetideEthinyl Estradiol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CaptoprilThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Captopril.Approved
CarbamazepineThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Carbamazepine.Approved, Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Ethinyl Estradiol.Experimental
CarmegliptinThe therapeutic efficacy of Carmegliptin can be decreased when used in combination with Ethinyl Estradiol.Investigational
CarprofenCarprofen may increase the thrombogenic activities of Ethinyl Estradiol.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
CefoperazoneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Cefoperazone.Approved, Investigational
CeftriaxoneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ceftriaxone.Approved
CelecoxibCelecoxib may increase the thrombogenic activities of Ethinyl Estradiol.Approved, Investigational
CeritinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Ethinyl Estradiol.Approved, Withdrawn
CertoparinEthinyl Estradiol may decrease the anticoagulant activities of Certoparin.Approved, Investigational
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Ethinyl Estradiol.Approved
ChloroformThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Chloroform.Vet Approved
ChlorpromazineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
ChlorprothixeneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CholestyramineCholestyramine can cause a decrease in the absorption of Ethinyl Estradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Cholic AcidThe risk or severity of liver damage can be increased when Cholic Acid is combined with Ethinyl Estradiol.Approved
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Ethinyl Estradiol.Experimental
CimicoxibCimicoxib may increase the thrombogenic activities of Ethinyl Estradiol.Investigational
ClarithromycinThe metabolism of Ethinyl Estradiol can be decreased when combined with Clarithromycin.Approved
ClobazamThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Clobazam.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Ethinyl Estradiol.Approved
ClobetasoneThe serum concentration of Clobetasone can be increased when it is combined with Ethinyl Estradiol.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Ethinyl Estradiol.Approved
ClofazimineThe risk or severity of liver damage can be increased when Ethinyl Estradiol is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Clomipramine.Approved, Investigational, Vet Approved
CloprednolThe serum concentration of Cloprednol can be increased when it is combined with Ethinyl Estradiol.Experimental
ClorindioneEthinyl Estradiol may decrease the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe risk or severity of liver damage can be increased when Ethinyl Estradiol is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Cobicistat.Approved
CodeineThe serum concentration of Codeine can be decreased when it is combined with Ethinyl Estradiol.Approved, Illicit
ColchicineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Colchicine.Approved
ColesevelamThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Colesevelam.Approved
ColestipolColestipol can cause a decrease in the absorption of Ethinyl Estradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Concanamycin AThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Concanamycin A.Experimental
Conestat alfaEthinyl Estradiol may increase the thrombogenic activities of Conestat alfa.Approved, Investigational
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
CorticotropinThe serum concentration of Corticotropin can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational, Vet Approved
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
CortivazolThe serum concentration of Cortivazol can be increased when it is combined with Ethinyl Estradiol.Investigational
CrizotinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Crizotinib.Approved
CurcuminThe metabolism of Ethinyl Estradiol can be decreased when combined with Curcumin.Approved, Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Ethinyl Estradiol.Approved
CyclosporineThe risk or severity of liver damage can be increased when Ethinyl Estradiol is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateEthinyl Estradiol may decrease the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Daclatasvir.Approved, Investigational
DactinomycinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dactinomycin.Approved, Investigational
DalteparinEthinyl Estradiol may decrease the anticoagulant activities of Dalteparin.Approved
DanaparoidEthinyl Estradiol may decrease the anticoagulant activities of Danaparoid.Approved, Withdrawn
DanazolThe metabolism of Ethinyl Estradiol can be decreased when combined with Danazol.Approved
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ethinyl Estradiol.Approved
DarexabanEthinyl Estradiol may decrease the anticoagulant activities of Darexaban.Investigational
DarunavirThe metabolism of Ethinyl Estradiol can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinEthinyl Estradiol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideEthinyl Estradiol may decrease the anticoagulant activities of Defibrotide.Approved, Investigational
DeflazacortThe serum concentration of Deflazacort can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
DelafloxacinThe serum concentration of Delafloxacin can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
DelavirdineThe metabolism of Ethinyl Estradiol can be decreased when combined with Delavirdine.Approved
DesipramineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Desipramine.Approved, Investigational
DesirudinEthinyl Estradiol may decrease the anticoagulant activities of Desirudin.Approved
DesmethylsertralineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Desmethylsertraline.Experimental
DesmoteplaseEthinyl Estradiol may decrease the anticoagulant activities of Desmoteplase.Investigational
DesonideThe serum concentration of Desonide can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Ethinyl Estradiol.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Ethinyl Estradiol.Vet Approved
DexniguldipineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dexniguldipine.Experimental
DextranEthinyl Estradiol may decrease the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DexverapamilThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dexverapamil.Experimental
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
DicoumarolEthinyl Estradiol may decrease the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Diethyl ether.Experimental
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Ethinyl Estradiol.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational, Withdrawn
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Ethinyl Estradiol.Approved
DigoxinEthinyl Estradiol may decrease the excretion rate of Digoxin which could result in a higher serum level.Approved
DihydroergotamineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe metabolism of Ethinyl Estradiol can be decreased when combined with Diltiazem.Approved, Investigational
DiphenadioneEthinyl Estradiol may decrease the anticoagulant activities of Diphenadione.Experimental
DipyridamoleEthinyl Estradiol may decrease the anticoagulant activities of Dipyridamole.Approved
DisopyramideThe therapeutic efficacy of Disopyramide can be decreased when used in combination with Ethinyl Estradiol.Approved
DitazoleEthinyl Estradiol may decrease the anticoagulant activities of Ditazole.Approved, Withdrawn
DofequidarThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dofequidar.Experimental, Investigational
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Ethinyl Estradiol.Approved
DovitinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dovitinib.Investigational
DoxazosinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Doxepin.Approved, Investigational
DoxofyllineThe serum concentration of Doxofylline can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
DoxorubicinEthinyl Estradiol may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineThe metabolism of Ethinyl Estradiol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dronedarone.Approved
Drotrecogin alfaEthinyl Estradiol may decrease the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
DuloxetineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Duloxetine.Approved
DutogliptinThe therapeutic efficacy of Dutogliptin can be decreased when used in combination with Ethinyl Estradiol.Investigational
EconazoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Econazole.Approved
Edetic AcidEthinyl Estradiol may decrease the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEthinyl Estradiol may decrease the anticoagulant activities of Edoxaban.Approved
EfavirenzThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Efavirenz.Approved, Investigational
ElacridarThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Elacridar.Investigational
ElagolixThe serum concentration of Elagolix can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Ethinyl Estradiol.Approved
EmopamilThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Emopamil.Experimental
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethinyl Estradiol.Approved
EnasidenibThe serum concentration of Enasidenib can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Ethinyl Estradiol.Experimental
EnoxaparinEthinyl Estradiol may decrease the anticoagulant activities of Enoxaparin.Approved
EntecavirThe serum concentration of Entecavir can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
EnzalutamideThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Enzalutamide.Approved
EpoprostenolEthinyl Estradiol may decrease the anticoagulant activities of Epoprostenol.Approved
ErgonovineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
Eslicarbazepine acetateThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Estramustine.Approved, Investigational
EtamiphyllineThe serum concentration of Etamiphylline can be increased when it is combined with Ethinyl Estradiol.Experimental
Ethyl biscoumacetateEthinyl Estradiol may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the thrombogenic activities of Ethinyl Estradiol.Approved, Investigational, Vet Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Ethinyl Estradiol.Approved
EtoricoxibEtoricoxib may increase the thrombogenic activities of Ethinyl Estradiol.Approved, Investigational
EtravirineThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Etravirine.Approved
EvogliptinThe therapeutic efficacy of Evogliptin can be decreased when used in combination with Ethinyl Estradiol.Investigational
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
ExenatideThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Exenatide.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Ethinyl Estradiol.Approved
EzogabineThe serum concentration of Ezogabine can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
FelbamateThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Felbamate.Approved
FelodipineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Felodipine.Approved, Investigational
FenethyllineThe serum concentration of Fenethylline can be increased when it is combined with Ethinyl Estradiol.Approved
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Ethinyl Estradiol.Approved
FentanylThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferulic acidEthinyl Estradiol may decrease the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinEthinyl Estradiol may decrease the anticoagulant activities of Fibrinolysin.Investigational
FirocoxibFirocoxib may increase the thrombogenic activities of Ethinyl Estradiol.Experimental, Vet Approved
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
FlucloroloneThe serum concentration of Fluclorolone can be increased when it is combined with Ethinyl Estradiol.Experimental
FluconazoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fluconazole.Approved, Investigational
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
FluindioneEthinyl Estradiol may decrease the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
FluocortinThe serum concentration of Fluocortin can be increased when it is combined with Ethinyl Estradiol.Experimental
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Ethinyl Estradiol.Approved, Withdrawn
FluoresceinEthinyl Estradiol may decrease the excretion rate of Fluorescein which could result in a higher serum level.Approved
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
FluoxetineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Flupentixol.Approved, Investigational, Withdrawn
FluperoloneThe serum concentration of Fluperolone can be increased when it is combined with Ethinyl Estradiol.Experimental
FluphenazineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Ethinyl Estradiol.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Ethinyl Estradiol.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Ethinyl Estradiol.Approved
FlurazepamThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Flurazepam.Approved, Illicit, Investigational
FlurbiprofenThe serum concentration of Flurbiprofen can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Ethinyl Estradiol.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Ethinyl Estradiol.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Ethinyl Estradiol.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Ethinyl Estradiol.Approved
FluvoxamineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FondaparinuxEthinyl Estradiol may decrease the anticoagulant activities of Fondaparinux.Approved, Investigational
FormocortalThe serum concentration of Formocortal can be increased when it is combined with Ethinyl Estradiol.Experimental
FosamprenavirThe metabolism of Ethinyl Estradiol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Fosaprepitant.Approved
FosphenytoinThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Fosphenytoin.Approved, Investigational
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
FurafyllineThe serum concentration of Furafylline can be increased when it is combined with Ethinyl Estradiol.Experimental
FurosemideThe serum concentration of Furosemide can be decreased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
Fusidic AcidThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabexateEthinyl Estradiol may decrease the anticoagulant activities of Gabexate.Investigational
GallopamilThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Gallopamil.Investigational
GanciclovirThe serum concentration of Ganciclovir can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
GavestinelThe serum concentration of Gavestinel can be decreased when it is combined with Ethinyl Estradiol.Investigational
GefitinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Ethinyl Estradiol.Approved
GemigliptinThe therapeutic efficacy of Gemigliptin can be decreased when used in combination with Ethinyl Estradiol.Investigational
GenisteinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Genistein.Investigational
GlecaprevirThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Glecaprevir.Approved, Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Ethinyl Estradiol.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Ethinyl Estradiol.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Ethinyl Estradiol.Approved
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
GlisoxepideThe therapeutic efficacy of Glisoxepide can be decreased when used in combination with Ethinyl Estradiol.Investigational
GlyburideThe risk or severity of liver damage can be increased when Glyburide is combined with Ethinyl Estradiol.Approved
GlycerinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Glycerin.Approved, Investigational
Glycochenodeoxycholic AcidEthinyl Estradiol may decrease the excretion rate of Glycochenodeoxycholic Acid which could result in a higher serum level.Experimental
GlycodiazineThe therapeutic efficacy of Glycodiazine can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
GosogliptinThe therapeutic efficacy of Gosogliptin can be decreased when used in combination with Ethinyl Estradiol.Investigational
Gramicidin DThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Gramicidin D.Approved
GriseofulvinThe metabolism of Ethinyl Estradiol can be increased when combined with Griseofulvin.Approved, Investigational, Vet Approved
GuanineThe serum concentration of Guanine can be increased when it is combined with Ethinyl Estradiol.Experimental
Guar gumThe therapeutic efficacy of Guar gum can be decreased when used in combination with Ethinyl Estradiol.Experimental
HalcinonideThe serum concentration of Halcinonide can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational, Withdrawn
HalometasoneThe serum concentration of Halometasone can be increased when it is combined with Ethinyl Estradiol.Experimental
HeparinEthinyl Estradiol may decrease the anticoagulant activities of Heparin.Approved, Investigational
HexobarbitalThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Hexobarbital.Approved
HM-30181The serum concentration of Ethinyl Estradiol can be increased when it is combined with HM-30181.Experimental
Human C1-esterase inhibitorEthinyl Estradiol may increase the thrombogenic activities of Human C1-esterase inhibitor.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
HycanthoneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Hycanthone.Approved, Investigational
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
Hydrocortisone aceponateThe serum concentration of Hydrocortisone aceponate can be increased when it is combined with Ethinyl Estradiol.Experimental, Vet Approved
Hydrocortisone acetateThe serum concentration of Hydrocortisone acetate can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
Hydrocortisone butyrateThe serum concentration of Hydrocortisone butyrate can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
Hydrocortisone probutateThe serum concentration of Hydrocortisone probutate can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
Hydrocortisone succinateThe serum concentration of Hydrocortisone succinate can be increased when it is combined with Ethinyl Estradiol.Approved
Hydrocortisone valerateThe serum concentration of Hydrocortisone valerate can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
HydroxychloroquineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Hydroxychloroquine.Approved
HypoxanthineThe serum concentration of Hypoxanthine can be increased when it is combined with Ethinyl Estradiol.Experimental
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Ethinyl Estradiol.Approved
IdelalisibThe metabolism of Ethinyl Estradiol can be decreased when combined with Idelalisib.Approved
IdraparinuxEthinyl Estradiol may decrease the anticoagulant activities of Idraparinux.Investigational
IloprostEthinyl Estradiol may decrease the anticoagulant activities of Iloprost.Approved, Investigational
ImatinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Imatinib.Approved
Immune Globulin HumanEthinyl Estradiol may increase the thrombogenic activities of Immune Globulin Human.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Ethinyl Estradiol.Approved
IndinavirThe metabolism of Ethinyl Estradiol can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Ethinyl Estradiol.Approved
Insulin BeefThe therapeutic efficacy of Insulin Beef can be decreased when used in combination with Ethinyl Estradiol.Approved
Insulin DegludecThe therapeutic efficacy of Insulin Degludec can be decreased when used in combination with Ethinyl Estradiol.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Ethinyl Estradiol.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ethinyl Estradiol.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Ethinyl Estradiol.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ethinyl Estradiol.Approved
Insulin peglisproThe therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Ethinyl Estradiol.Investigational
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ethinyl Estradiol.Approved
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
IsavuconazoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Ethinyl Estradiol can be decreased when combined with Isoniazid.Approved, Investigational
IsotretinoinThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Isotretinoin.Approved
IsradipineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Ethinyl Estradiol can be decreased when combined with Itraconazole.Approved, Investigational
IvermectinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ivermectin.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ivosidenib.Approved, Investigational
KetoconazoleThe risk or severity of liver damage can be increased when Ethinyl Estradiol is combined with Ketoconazole.Approved, Investigational
KetoprofenThe serum concentration of Ketoprofen can be decreased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
KRP-104The therapeutic efficacy of KRP-104 can be decreased when used in combination with Ethinyl Estradiol.Investigational
LaniquidarThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Laniquidar.Investigational
LansoprazoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ledipasvir.Approved
LenalidomideEthinyl Estradiol may increase the thrombogenic activities of Lenalidomide.Approved
LenvatinibThe risk or severity of liver damage can be increased when Ethinyl Estradiol is combined with Lenvatinib.Approved, Investigational
LepirudinEthinyl Estradiol may decrease the anticoagulant activities of Lepirudin.Approved
LetaxabanEthinyl Estradiol may decrease the anticoagulant activities of Letaxaban.Investigational
LetermovirThe serum concentration of Letermovir can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
LevofloxacinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Ethinyl Estradiol.Approved
LidocaineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Linagliptin.Approved
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Ethinyl Estradiol.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Ethinyl Estradiol.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Ethinyl Estradiol.Approved
LisofyllineThe serum concentration of Lisofylline can be increased when it is combined with Ethinyl Estradiol.Investigational
LixisenatideThe therapeutic efficacy of Lixisenatide can be decreased when used in combination with Ethinyl Estradiol.Approved
LobeglitazoneThe therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
LobucavirThe serum concentration of Lobucavir can be increased when it is combined with Ethinyl Estradiol.Investigational
LomerizineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Lomerizine.Experimental
LomitapideThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Lomitapide.Approved, Investigational
LonafarnibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Lonafarnib.Investigational
LoperamideThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Ethinyl Estradiol can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Loratadine.Approved, Investigational
LorpiprazoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Ethinyl Estradiol.Approved
LoteprednolThe serum concentration of Loteprednol can be increased when it is combined with Ethinyl Estradiol.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
LoxapineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the thrombogenic activities of Ethinyl Estradiol.Approved, Investigational
LusutrombopagThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Lusutrombopag.Approved, Investigational
MecaserminThe therapeutic efficacy of Mecasermin can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Ethinyl Estradiol.Approved
MefloquineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Mefloquine.Approved, Investigational
Megestrol acetateThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MelagatranEthinyl Estradiol may decrease the anticoagulant activities of Melagatran.Experimental
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Ethinyl Estradiol.Vet Approved
MeloxicamMeloxicam may increase the thrombogenic activities of Ethinyl Estradiol.Approved, Vet Approved
MeprednisoneThe serum concentration of Meprednisone can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
MetahexamideThe therapeutic efficacy of Metahexamide can be decreased when used in combination with Ethinyl Estradiol.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Ethinyl Estradiol.Approved
MethadoneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Methadone.Approved
MethohexitalThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Methohexital.Approved
MethylphenobarbitalThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
MetreleptinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Metreleptin.Approved
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Ethinyl Estradiol.Approved
MibefradilThe metabolism of Ethinyl Estradiol can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Ethinyl Estradiol.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
MitotaneThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Modafinil.Approved, Investigational
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
Mometasone furoateThe serum concentration of Mometasone furoate can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
MonensinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Monensin.Vet Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
MuraglitazarThe serum concentration of Muraglitazar can be decreased when it is combined with Ethinyl Estradiol.Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
NabumetoneNabumetone may increase the thrombogenic activities of Ethinyl Estradiol.Approved
NadroparinEthinyl Estradiol may decrease the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatEthinyl Estradiol may decrease the anticoagulant activities of Nafamostat.Approved, Investigational
NafcillinThe metabolism of Ethinyl Estradiol can be increased when combined with Nafcillin.Approved, Investigational
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
NaltrexoneThe serum concentration of Naltrexone can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational, Vet Approved
NaproxenThe serum concentration of Naproxen can be decreased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
NBI-6024The therapeutic efficacy of NBI-6024 can be decreased when used in combination with Ethinyl Estradiol.Investigational
NefazodoneThe metabolism of Ethinyl Estradiol can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Nelfinavir.Approved
NepafenacNepafenac may increase the thrombogenic activities of Ethinyl Estradiol.Approved, Investigational
NeratinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Neratinib.Approved, Investigational
NetoglitazoneThe therapeutic efficacy of Netoglitazone can be decreased when used in combination with Ethinyl Estradiol.Experimental
NetupitantThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Nicardipine.Approved, Investigational
Niflumic AcidNiflumic Acid may increase the thrombogenic activities of Ethinyl Estradiol.Approved
NigericinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Nigericin.Experimental
NiguldipineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Niguldipine.Experimental
NilotinibThe metabolism of Ethinyl Estradiol can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the thrombogenic activities of Ethinyl Estradiol.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Nimodipine.Approved, Investigational
NisoldipineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Nitrendipine.Approved, Investigational
NN344The therapeutic efficacy of NN344 can be decreased when used in combination with Ethinyl Estradiol.Investigational
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
OlaparibThe metabolism of Ethinyl Estradiol can be decreased when combined with Olaparib.Approved
OmarigliptinThe therapeutic efficacy of Omarigliptin can be decreased when used in combination with Ethinyl Estradiol.Investigational
OmbitasvirEthinyl Estradiol may increase the hepatotoxic activities of Ombitasvir.Approved, Investigational
OmeprazoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
ONT-093The serum concentration of Ethinyl Estradiol can be increased when it is combined with ONT-093.Investigational
OsimertinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Osimertinib.Approved
OspemifeneThe risk or severity of adverse effects can be increased when Ethinyl Estradiol is combined with Ospemifene.Approved, Investigational
OtamixabanEthinyl Estradiol may decrease the anticoagulant activities of Otamixaban.Investigational
OxtriphyllineThe serum concentration of Oxtriphylline can be increased when it is combined with Ethinyl Estradiol.Approved
PaclitaxelEthinyl Estradiol may decrease the excretion rate of Paclitaxel which could result in a higher serum level.Approved, Vet Approved
PalbociclibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Paliperidone.Approved
PantoprazoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Pantoprazole.Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Ethinyl Estradiol.Approved
ParecoxibParecoxib may increase the thrombogenic activities of Ethinyl Estradiol.Approved
ParitaprevirEthinyl Estradiol may increase the hepatotoxic activities of Paritaprevir.Approved, Investigational
ParnaparinEthinyl Estradiol may decrease the anticoagulant activities of Parnaparin.Approved, Investigational
ParoxetineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Paroxetine.Approved, Investigational
PeldesineThe serum concentration of Peldesine can be increased when it is combined with Ethinyl Estradiol.Experimental, Investigational
PemetrexedThe serum concentration of Pemetrexed can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
PenciclovirThe serum concentration of Penciclovir can be increased when it is combined with Ethinyl Estradiol.Approved
PentamidineThe therapeutic efficacy of Pentamidine can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
PentazocineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Pentazocine.Approved, Vet Approved
PentifyllineThe serum concentration of Pentifylline can be increased when it is combined with Ethinyl Estradiol.Experimental
PentobarbitalThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Pentobarbital.Approved, Investigational, Vet Approved
Pentosan PolysulfateEthinyl Estradiol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe serum concentration of Pentoxifylline can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
PethidineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Pethidine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational, Withdrawn
PhenindioneEthinyl Estradiol may decrease the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenprocoumonEthinyl Estradiol may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenytoinThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Pibrentasvir.Approved, Investigational
PimozideThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
PitolisantThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Pitolisant.Approved, Investigational
PonatinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ponatinib.Approved, Investigational
PosaconazoleThe metabolism of Ethinyl Estradiol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium CitrateEthinyl Estradiol may decrease the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Ethinyl Estradiol.Approved, Investigational, Nutraceutical
PrasugrelEthinyl Estradiol may decrease the anticoagulant activities of Prasugrel.Approved
PravastatinEthinyl Estradiol may decrease the excretion rate of Pravastatin which could result in a higher serum level.Approved
PrazosinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Prazosin.Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
PrednisoneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Prednisone.Approved, Vet Approved
PrednylideneThe serum concentration of Prednylidene can be increased when it is combined with Ethinyl Estradiol.Experimental
PrimaquineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Primaquine.Approved
PrimidoneThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProgesteroneThe risk or severity of liver damage can be increased when Ethinyl Estradiol is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Propafenone.Approved
PropentofyllineThe serum concentration of Propentofylline can be increased when it is combined with Ethinyl Estradiol.Investigational
PropofolThe serum concentration of Propofol can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational, Vet Approved
Protein CEthinyl Estradiol may decrease the anticoagulant activities of Protein C.Approved
Protein S humanEthinyl Estradiol may decrease the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEthinyl Estradiol may decrease the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Protriptyline.Approved
ProxyphyllineThe serum concentration of Proxyphylline can be increased when it is combined with Ethinyl Estradiol.Experimental
PrucaloprideThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Prucalopride.Approved
QuercetinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Quercetin.Experimental, Investigational
QuinacrineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Quinacrine.Approved, Investigational
QuinidineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Ethinyl Estradiol can be increased when combined with Quinine.Approved
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Ethinyl Estradiol.Approved
RanitidineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ranitidine.Approved
ReboxetineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Regorafenib.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
ReserpineThe risk or severity of liver damage can be increased when Ethinyl Estradiol is combined with Reserpine.Approved, Investigational
ReteplaseEthinyl Estradiol may decrease the anticoagulant activities of Reteplase.Approved, Investigational
Reversin 121The serum concentration of Ethinyl Estradiol can be increased when it is combined with Reversin 121.Experimental
ReviparinEthinyl Estradiol may decrease the anticoagulant activities of Reviparin.Approved, Investigational
RifampicinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Rifampicin.Approved
RifamycinThe metabolism of Ethinyl Estradiol can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Ethinyl Estradiol can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Ethinyl Estradiol can be increased when combined with Rifaximin.Approved, Investigational
RilpivirineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Rilpivirine.Approved
RimexoloneThe metabolism of Ethinyl Estradiol can be increased when combined with Rimexolone.Approved
RisperidoneThe metabolism of Ethinyl Estradiol can be decreased when combined with Risperidone.Approved, Investigational
RitonavirEthinyl Estradiol may increase the hepatotoxic activities of Ritonavir.Approved, Investigational
RivaroxabanEthinyl Estradiol may decrease the anticoagulant activities of Rivaroxaban.Approved
RivoglitazoneThe therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Ethinyl Estradiol.Experimental, Investigational
RobenacoxibRobenacoxib may increase the thrombogenic activities of Ethinyl Estradiol.Experimental, Vet Approved
RofecoxibRofecoxib may increase the thrombogenic activities of Ethinyl Estradiol.Approved, Investigational, Withdrawn
RolapitantThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Rolapitant.Approved, Investigational
RopiniroleEthinyl Estradiol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
RosuvastatinEthinyl Estradiol may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.Approved
RucaparibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Rucaparib.Approved, Investigational
RufinamideThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Rufinamide.Approved
SalinomycinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Salinomycin.Vet Approved
SaquinavirThe metabolism of Ethinyl Estradiol can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Sarilumab.Approved, Investigational
SaruplaseEthinyl Estradiol may decrease the anticoagulant activities of Saruplase.Experimental
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Ethinyl Estradiol.Approved
SecobarbitalThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational, Vet Approved
SemaglutideThe therapeutic efficacy of Semaglutide can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
SertralineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Sertraline.Approved
SiltuximabThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Ethinyl Estradiol.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
Sodium CitrateEthinyl Estradiol may decrease the anticoagulant activities of Sodium Citrate.Approved, Investigational
SomatotropinThe therapeutic efficacy of Somatotropin can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
SorafenibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Sorafenib.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Ethinyl Estradiol.Investigational
St. John's WortThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StaurosporineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Stiripentol.Approved
StreptokinaseEthinyl Estradiol may decrease the anticoagulant activities of Streptokinase.Approved, Investigational
SulfadiazineThe therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational, Vet Approved
SulfamethoxazoleThe therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Ethinyl Estradiol.Approved
SulfisoxazoleThe therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Ethinyl Estradiol.Approved, Vet Approved
SulodexideEthinyl Estradiol may decrease the anticoagulant activities of Sulodexide.Approved, Investigational
SunitinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenThe serum concentration of Suprofen can be decreased when it is combined with Ethinyl Estradiol.Approved, Withdrawn
SuvorexantThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Suvorexant.Approved, Investigational
TacrolimusThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Tacrolimus.Approved, Investigational
TalniflumateTalniflumate may increase the thrombogenic activities of Ethinyl Estradiol.Approved
TamoxifenThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Tamoxifen.Approved
TariquidarThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Tariquidar.Investigational
TaspoglutideThe therapeutic efficacy of Taspoglutide can be decreased when used in combination with Ethinyl Estradiol.Investigational
Taurocholic AcidEthinyl Estradiol may decrease the excretion rate of Taurocholic Acid which could result in a higher serum level.Experimental
TelaprevirThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Ethinyl Estradiol can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Temsirolimus.Approved
TenecteplaseEthinyl Estradiol may decrease the anticoagulant activities of Tenecteplase.Approved
TeneligliptinThe therapeutic efficacy of Teneligliptin can be decreased when used in combination with Ethinyl Estradiol.Investigational
TerfenadineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Terfenadine.Approved, Withdrawn
TesmilifeneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Testosterone enanthate.Approved
Testosterone propionateThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Testosterone propionate.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetrandrineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Tetrandrine.Experimental
ThalidomideEthinyl Estradiol may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe serum concentration of Theobromine can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
TheodrenalineThe serum concentration of Theodrenaline can be increased when it is combined with Ethinyl Estradiol.Investigational
ThiamylalThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Thiamylal.Approved, Vet Approved
ThiopentalThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Thiopental.Approved, Vet Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Ethinyl Estradiol.Approved
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
TicagrelorEthinyl Estradiol may decrease the anticoagulant activities of Ticagrelor.Approved
TinzaparinEthinyl Estradiol may decrease the anticoagulant activities of Tinzaparin.Approved
TioclomarolEthinyl Estradiol may decrease the anticoagulant activities of Tioclomarol.Experimental
TipifarnibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Tipifarnib.Investigational
TipranavirThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Ethinyl Estradiol.Approved, Withdrawn
TocilizumabThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Tocilizumab.Approved
TocopherylquinoneEthinyl Estradiol may decrease the anticoagulant activities of Tocopherylquinone.Experimental, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
TolvaptanThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Tolvaptan.Approved
TopiramateThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Topiramate.Approved
ToremifeneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Toremifene.Approved, Investigational
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
Tranexamic AcidEthinyl Estradiol may increase the thrombogenic activities of Tranexamic Acid.Approved
TretinoinThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
TrifluoperazineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Trifluoperazine.Approved, Investigational
TriflupromazineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrifluridineThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Trifluridine.Approved, Investigational
TriflusalEthinyl Estradiol may decrease the anticoagulant activities of Triflusal.Approved, Investigational
TrilostaneThe serum concentration of Trilostane can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational, Vet Approved, Withdrawn
TrimethoprimThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Ethinyl Estradiol.Investigational, Withdrawn
TroleandomycinThe metabolism of Ethinyl Estradiol can be decreased when combined with Troleandomycin.Approved
TroxerutinEthinyl Estradiol may decrease the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe serum concentration of Ulobetasol can be increased when it is combined with Ethinyl Estradiol.Approved
Uric AcidThe serum concentration of Uric Acid can be increased when it is combined with Ethinyl Estradiol.Experimental, Investigational
UrokinaseEthinyl Estradiol may decrease the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
ValaciclovirThe serum concentration of Valaciclovir can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
ValdecoxibValdecoxib may increase the thrombogenic activities of Ethinyl Estradiol.Approved, Investigational, Withdrawn
ValganciclovirThe serum concentration of Valganciclovir can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
ValinomycinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Valinomycin.Experimental
ValomaciclovirThe serum concentration of Valomaciclovir can be increased when it is combined with Ethinyl Estradiol.Investigational
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
ValspodarThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Valspodar.Investigational
VelpatasvirThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Velpatasvir.Approved, Investigational
VemurafenibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Verapamil.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
VinblastineThe risk or severity of liver damage can be increased when Ethinyl Estradiol is combined with Vinblastine.Approved
VincristineEthinyl Estradiol may decrease the excretion rate of Vincristine which could result in a higher serum level.Approved, Investigational
VoacamineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Voacamine.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
VorapaxarEthinyl Estradiol may decrease the anticoagulant activities of Vorapaxar.Approved
VoxilaprevirThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Voxilaprevir.Approved, Investigational
WarfarinEthinyl Estradiol may decrease the anticoagulant activities of Warfarin.Approved
XanthineThe serum concentration of Xanthine can be increased when it is combined with Ethinyl Estradiol.Experimental
XimelagatranEthinyl Estradiol may decrease the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
YohimbineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Yohimbine.Approved, Investigational, Vet Approved
ZidovudineThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Zidovudine.Approved
ZiprasidoneThe metabolism of Ethinyl Estradiol can be decreased when combined with Ziprasidone.Approved
ZomepiracThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Zomepirac.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
ZosuquidarThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Zosuquidar.Investigational
Food Interactions
Not Available

References

Synthesis Reference

Andreas Sachse, "Method of female hormonal contraception using a fixed extended cycle hormonal preparation containing dienogest and ethinyl estradiol." U.S. Patent US20060079491, issued April 13, 2006.

US20060079491
General References
Not Available
External Links
Human Metabolome Database
HMDB0001926
KEGG Drug
D00554
KEGG Compound
C07534
PubChem Compound
5991
PubChem Substance
46508618
ChemSpider
5770
BindingDB
50187243
ChEBI
4903
ChEMBL
CHEMBL691
Therapeutic Targets Database
DAP001018
PharmGKB
PA449527
HET
3WF
RxList
RxList Drug Page
Wikipedia
Ethinylestradiol
ATC Codes
G03AA03 — Lynestrenol and ethinylestradiolG03AA04 — Megestrol and ethinylestradiolG03AB07 — Chlormadinone and ethinylestradiolG03AA08 — Medroxyprogesterone and ethinylestradiolG03AA10 — Gestodene and ethinylestradiolG03AB05 — Desogestrel and ethinylestradiolG03AA09 — Desogestrel and ethinylestradiolG03AB01 — Megestrol and ethinylestradiolG03AA11 — Norgestimate and ethinylestradiolG03AB02 — Lynestrenol and ethinylestradiolG03CA01 — EthinylestradiolL02AA03 — EthinylestradiolG03AB03 — Levonorgestrel and ethinylestradiolG03AA12 — Drospirenone and ethinylestradiolG03AA07 — Levonorgestrel and ethinylestradiolG03AA05 — Norethisterone and ethinylestradiolG03AA02 — Quingestanol and ethinylestradiolG03AA01 — Etynodiol and ethinylestradiolG03AB04 — Norethisterone and ethinylestradiolG03AB06 — Gestodene and ethinylestradiolG03AA13 — Norelgestromin and ethinylestradiolG03AA15 — Chlormadinone and ethinylestradiolG03AA06 — Norgestrel and ethinylestradiolG03AA16 — Dienogest and ethinylestradiol
AHFS Codes
  • 68:16.04 — Estrogens
PDB Entries
4x1f / 4x1g
FDA label
Download (470 KB)
MSDS
Download (73.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingSupportive CareEndometriosis of Uterus1
1CompletedNot AvailableBioequivalence1
1CompletedNot AvailableHealthy Volunteers4
1CompletedNot AvailableHepatitis C Viral Infection1
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
1CompletedBasic ScienceFollicle Count / Follicle Size / Induction of follicle development / Oral Contraceptives (OC) / Ovarian Follicle1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics of Mirabegron1
1CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections / Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS)1
1CompletedOtherHealthy Female Volunteers / Type 2 Diabetes Mellitus1
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentArthritic Psoriasis / Inflammatory Bowel Diseases (IBD) / Psoriasis / Systemic Lupus Erythematosus (SLE)1
1CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
1CompletedTreatmentContraception2
1CompletedTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus1
1CompletedTreatmentHealthy Volunteers5
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS)1
1CompletedTreatmentMajor Depressive Disorder (MDD)1
1CompletedTreatmentRheumatoid Arthritis1
1CompletedTreatmentType 2 Diabetes Mellitus2
1Not Yet RecruitingBasic ScienceHealthy Females1
1Not Yet RecruitingTreatmentMalignancies, Hematologic1
1RecruitingOtherHealthy Volunteers1
1RecruitingPreventionContraception1
1RecruitingTreatmentDrug Interactions1
1RecruitingTreatmentTumors, Solid1
1TerminatedNot AvailableCystic Fibrosis Exacerbations While on and Off Hormonal Contraception1
1TerminatedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
1TerminatedHealth Services ResearchHuman Immunodeficiency Virus (HIV)1
1TerminatedTreatmentHealthy Volunteers1
1Unknown StatusTreatmentPolycystic Ovaries Syndrome1
1WithdrawnBasic ScienceHealthy Volunteers1
1, 2CompletedPreventionContraception / Hemostasis Parameter / Liver Metabolism1
2Active Not RecruitingTreatmentPolycystic Ovarian Syndrome1
2CompletedBasic ScienceHemostasis / Oral Contraceptives (OC)2
2CompletedPreventionBreakthrough Bleeding1
2CompletedPreventionContraception2
2CompletedPreventionEndometrial Cancers1
2CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Pregnancy1
2CompletedPreventionMigraines1
2CompletedPreventionPrevention of Pregnancy1
2CompletedTreatmentBone Mineral Density1
2CompletedTreatmentContraception1
2CompletedTreatmentContraception / Ovulation Inhibition1
2CompletedTreatmentDysmenorrhea1
2CompletedTreatmentOral Contraceptives (OC)1
2CompletedTreatmentOvulation1
2CompletedTreatmentOvulation Suppression1
2RecruitingTreatmentAnorexia Nervosa (AN)1
2RecruitingTreatmentPolycystic Ovarian Syndrome1
2TerminatedTreatmentContraception / Ovulation Inhibition1
2TerminatedTreatmentDepression / PMDD / Premenstrual Dysphoric Disorder / Premenstrual Syndrome1
2TerminatedTreatmentHidradenitis Suppurativa (HS)1
2Unknown StatusTreatmentContraception1
2, 3CompletedTreatmentFailed Induction of Labor1
3Active Not RecruitingTreatmentContraception1
3CompletedEducational/Counseling/TrainingOral Contraceptives (OC)1
3CompletedPreventionContraception12
3CompletedPreventionContraception / Neural Tube Defects (NTDs) / Oral Contraceptives (OC)1
3CompletedPreventionContraception / Oral Contraceptives (OC) / Ovulation Inhibition1
3CompletedPreventionPregnancy Prevention1
3CompletedTreatmentAcne Vulgaris4
3CompletedTreatmentContraception1
3CompletedTreatmentDysmenorrhea1
3CompletedTreatmentHealthy Volunteers5
3CompletedTreatmentOral Contraceptives (OC)1
3CompletedTreatmentPolycystic Ovaries Syndrome2
3CompletedTreatmentPremenstrual Dysphoric Disorder ( PMDD)1
3CompletedTreatmentPremenstrual Syndrome1
3CompletedTreatmentPrimary Dysmenorrhoea1
3CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
3CompletedTreatmentTurner's Syndrome1
3RecruitingTreatmentBladder Cancers / Transitional Cell Carcinoma / Ureteral Cancer1
3RecruitingTreatmentCancer, Breast1
3RecruitingTreatmentExercise-related Amenorrhea1
3RecruitingTreatmentPrimary Ovarian Insufficiency1
3TerminatedPreventionContraception1
3Unknown StatusNot AvailableContraceptive Affecting Blood Pressure / Contraceptive Affecting the Autonomic Nervous System1
3Unknown StatusTreatmentOral Contraceptives (OC)1
3WithdrawnNot AvailableMetrorrhagia1
3WithdrawnTreatmentOsteopenia1
4Active Not RecruitingBasic ScienceBone; Disorder, Development and Growth1
4Active Not RecruitingBasic ScienceOther Disorders of Bone Development and Growth1
4Active Not RecruitingPreventionBacterial Vaginosis (BV) / Human Immunodeficiency Virus (HIV)1
4CompletedBasic ScienceAdverse Effect of Oral Contraceptives, Subsequent Encounter1
4CompletedBasic ScienceContraception1
4CompletedDiagnosticBody Weights / Contraceptive Usage1
4CompletedPreventionBMI >30 kg/m2 / Cardiovascular Disease (CVD) / Insulin Resistance / Metabolic Syndromes1
4CompletedPreventionContraception1
4CompletedScreeningCardiovascular Risks / Insulin Sensitivity / Perimenopausal Disorder1
4CompletedTreatmentContraception2
4CompletedTreatmentContraception / Menopause / Quality of Life1
4CompletedTreatmentEmergency Contraception1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentInfertilities2
4CompletedTreatmentPolycystic Ovaries Syndrome3
4CompletedTreatmentPremature Ovarian Failure (POF)1
4CompletedTreatmentPremenstrual Dysphoric Disorder1
4CompletedTreatmentPremenstrual Syndrome1
4CompletedTreatmentPrimary Dysmenorrhoea1
4Enrolling by InvitationTreatmentBody Weight Changes1
4Not Yet RecruitingPreventionEmergency Contraception / Healthy, Reproductive Age Women1
4RecruitingBasic ScienceContraception1
4RecruitingPreventionBacterial Vaginosis (BV)1
4RecruitingTreatmentContraception / Human Immunodeficiency Virus (HIV)1
4RecruitingTreatmentDysmenorrhea / Endometriosis / Interstitial Cystitis / Migraine Disorders / Pain, Chronic / Pelvic Pain / Visceral Pain1
4TerminatedNot AvailableInfertilities1
4TerminatedScreeningContraception / Hypercoagulability1
4TerminatedTreatmentAbnormal Uterine Bleeding, Unspecified / Uterine Bleeding Heavy1
4Unknown StatusNot AvailableDysmenorrhea / Endometriotic Cysts / Painful Intercourse / Pelvic Pain1
4Unknown StatusPreventionHyperandrogenism / Menstrual Irregularities / Polycystic Ovarian Syndrome1
4Unknown StatusTreatmentBacterial Vaginosis (BV)1
4Unknown StatusTreatmentContraceptive Methods Comparison1
4Unknown StatusTreatmentMenstrual Problem1
4WithdrawnTreatmentInfertilities1
Not AvailableActive Not RecruitingNot AvailableContraception / Human Immunodeficiency Virus (HIV) / Immune Cells (Mucosal and Systemic)1
Not AvailableActive Not RecruitingNot AvailableDysmenorrhea1
Not AvailableActive Not RecruitingTreatmentEndometriosis / Infertilities1
Not AvailableCompletedNot AvailableAcne Vulgaris2
Not AvailableCompletedNot AvailableAcne / Contraception / Premenstrual Syndrome1
Not AvailableCompletedNot AvailableContraception4
Not AvailableCompletedNot AvailableContraceptive Usage / Vaginal Epithelial Disruption1
Not AvailableCompletedNot AvailableHormonal Contraception1
Not AvailableCompletedNot AvailableMetabolic Syndromes / Polycystic Ovaries Syndrome1
Not AvailableCompletedNot AvailablePharmacokinetics1
Not AvailableCompletedBasic ScienceCoronary Heart Disease (CHD)1
Not AvailableCompletedHealth Services ResearchOvarian Follicle1
Not AvailableCompletedTreatmentContraception1
Not AvailableCompletedTreatmentContraception: Optional Applicator for Insertion of Vaginal Ring1
Not AvailableCompletedTreatmentDepression / Premenstrual Syndrome1
Not AvailableCompletedTreatmentEmotional / Headaches / Pelvic Pain1
Not AvailableCompletedTreatmentHealthy Volunteers1
Not AvailableCompletedTreatmentHypermenorrhea1
Not AvailableCompletedTreatmentInsulin Resistance / Polycystic Ovaries Syndrome1
Not AvailableCompletedTreatmentSystemic Lupus Erythematosus (SLE)1
Not AvailableCompletedTreatmentTemporomandibular Joint Disorders1
Not AvailableCompletedTreatmentThrombosis, Venous1
Not AvailableNot Yet RecruitingTreatmentPremature Menopause / Primary Ovarian Insufficiency1
Not AvailableRecruitingNot AvailableInfertilities1
Not AvailableRecruitingBasic ScienceCystic Fibrosis (CF)1
Not AvailableRecruitingTreatmentHyperandrogenism / Metabolic Cardiovascular Syndrome1
Not AvailableTerminatedBasic ScienceContraception1
Not AvailableTerminatedPreventionAdolescents Seeking Contraception / Contraception Desired1
Not AvailableTerminatedTreatmentIn-Vitro Fertilization / Infertilities1
Not AvailableUnknown StatusBasic ScienceOral Contraceptives (OC)1
Not AvailableUnknown StatusTreatmentEndothelial Dysfunction / Polycystic Ovaries Syndrome1
Not AvailableUnknown StatusTreatmentFemale Contraception1
Not AvailableWithdrawnTreatmentDysmenorrhea / Menstruation Disorders / Menstruation Disturbances1

Pharmacoeconomics

Manufacturers
  • Schering corp sub schering plough corp
  • Pharmacia and upjohn co
  • Organon usa inc
Packagers
  • Amerisource Health Services Corp.
  • Barr Pharmaceuticals
  • Bayer Healthcare
  • Dept Health Central Pharmacy
  • Duramed
  • Mckesson Corp.
  • NV Organon
  • Organon Pharmaceuticals
  • Ortho Mcneil Janssen Pharmaceutical Inc.
  • Ortho-McNeil-Janssen Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Physicians Total Care Inc.
  • Prasco Labs
  • Schering Corp.
  • Spectrum Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral.05 mg
TabletOral.5 mg
TabletOral.02 mg
Patch, extended releaseTransdermal
Tablet, film coatedOral
Tablet, chewableOral
TabletOral
Kit
KitOral
Insert, extended releaseVaginal
RingVaginal
PatchTransdermal
Kit
Prices
Unit descriptionCostUnit
Ethinyl estradiol powder140.0USD g
Ortho-Cyclen (28) 28 0.25-35 mg-mcg tablet Disp Pack38.99USD disp
Ortho tri-cyclen lo tablet2.68USD tablet
Ortho-cyclen 28 tablet1.13USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6156742No2000-12-052020-12-05Us
US6787531No2000-08-312020-08-31Us
US6933395No1997-08-112017-08-11Us
US5876746No1995-11-202015-11-20Us
US5989581No1998-04-082018-04-08Us
US6214815Yes1999-12-092019-12-09Us
US6667050No1999-04-062019-04-06Us
US5898032No1997-06-232017-06-23Us
USRE39861No1997-06-232017-06-23Us
US6987101No1997-12-222017-12-22Us
US7163931No2001-12-202021-12-20Us
US6958326No2001-12-202021-12-20Us
US5798338No1995-07-102015-07-10Us
US7320969No2004-01-302024-01-30Us
US7615545No2003-06-152023-06-15Us
US7855190No2008-12-052028-12-05Us
US7858605No2003-06-232023-06-23Us
US6500814No1998-09-032018-09-03Us
US7704984No2009-02-022029-02-02Us
US6441168No2002-07-302022-07-30Us
US8617597No2010-02-082030-02-08Us
US8450299No2005-10-072025-10-07Us
US8415332No2009-03-112029-03-11Us
US6652880No2000-03-292020-03-29Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)142-144Inhoffen, H.H. and Hohlweg, W.; U.S. Patent 2,265,976; December 9, 1941; assigned to Schering Corp.
water solubility11.3 mg/L (at 27 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.67HANSCH,C ET AL. (1995)
logS-4.3ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00677 mg/mLALOGPS
logP3.63ALOGPS
logP3.9ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)10.33ChemAxon
pKa (Strongest Basic)-1.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area40.46 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity87.37 m3·mol-1ChemAxon
Polarizability34.53 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9965
Blood Brain Barrier+0.8546
Caco-2 permeable+0.8638
P-glycoprotein substrateSubstrate0.6892
P-glycoprotein inhibitor INon-inhibitor0.9006
P-glycoprotein inhibitor IINon-inhibitor0.9449
Renal organic cation transporterNon-inhibitor0.84
CYP450 2C9 substrateNon-substrate0.7178
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.715
CYP450 1A2 substrateInhibitor0.8941
CYP450 2C9 inhibitorNon-inhibitor0.9186
CYP450 2D6 inhibitorNon-inhibitor0.9506
CYP450 2C19 inhibitorNon-inhibitor0.6641
CYP450 3A4 inhibitorInhibitor0.5224
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6776
Ames testNon AMES toxic0.9155
CarcinogenicityNon-carcinogens0.8519
BiodegradationNot ready biodegradable0.9879
Rat acute toxicity2.4584 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8805
hERG inhibition (predictor II)Inhibitor0.5788
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.42 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-03di-0890000000-5219bc8ac1212313c9c0
Mass Spectrum (Electron Ionization)MSsplash10-03dj-2980000000-831c8190c59f98fc8623
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-000b-0290000000-0ef72fb5e00440b9ff50
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-000i-0960000000-945d82a0ab94f246ac88
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-056s-2910000000-0d38daebb87a39304e91
MS/MS Spectrum - EI-B (HITACHI M-80) , PositiveLC-MS/MSsplash10-03di-0890000000-7a166e952207cf7bc1d3
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Estrane steroids
Direct Parent
Estrogens and derivatives
Alternative Parents
3-hydroxysteroids / 17-hydroxysteroids / Phenanthrenes and derivatives / Tetralins / 1-hydroxy-2-unsubstituted benzenoids / Ynones / Tertiary alcohols / Cyclic alcohols and derivatives / Acetylides / Hydrocarbon derivatives
Substituents
Estrogen-skeleton / 3-hydroxysteroid / Hydroxysteroid / 17-hydroxysteroid / Phenanthrene / Tetralin / 1-hydroxy-2-unsubstituted benzenoid / Benzenoid / Ynone / Cyclic alcohol
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
terminal acetylenic compound, 17-hydroxy steroid, 3-hydroxy steroid (CHEBI:4903) / C18 steroids (estrogens) and derivatives (C07534) / C18 steroids (estrogens) and derivatives (LMST02010036)

Targets

Details
1. Estrogen receptor alpha
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
Gene Name
ESR1
Uniprot ID
P03372
Uniprot Name
Estrogen receptor
Molecular Weight
66215.45 Da
References
  1. Micevych PE, Chaban V, Ogi J, Dewing P, Lu JK, Sinchak K: Estradiol stimulates progesterone synthesis in hypothalamic astrocyte cultures. Endocrinology. 2007 Feb;148(2):782-9. Epub 2006 Nov 9. [PubMed:17095591]
  2. Garcia-Segura LM, Sanz A, Mendez P: Cross-talk between IGF-I and estradiol in the brain: focus on neuroprotection. Neuroendocrinology. 2006;84(4):275-9. Epub 2006 Nov 23. [PubMed:17124377]
  3. Brama M, Gnessi L, Basciani S, Cerulli N, Politi L, Spera G, Mariani S, Cherubini S, Scotto d'Abusco A, Scandurra R, Migliaccio S: Cadmium induces mitogenic signaling in breast cancer cell by an ERalpha-dependent mechanism. Mol Cell Endocrinol. 2007 Jan 29;264(1-2):102-8. Epub 2006 Nov 27. [PubMed:17125913]
  4. Lehnes K, Winder AD, Alfonso C, Kasid N, Simoneaux M, Summe H, Morgan E, Iann MC, Duncan J, Eagan M, Tavaluc R, Evans CH Jr, Russell R, Wang A, Hu F, Stoica A: The effect of estradiol on in vivo tumorigenesis is modulated by the human epidermal growth factor receptor 2/phosphatidylinositol 3-kinase/Akt1 pathway. Endocrinology. 2007 Mar;148(3):1171-80. Epub 2006 Nov 30. [PubMed:17138652]
  5. Mukai H, Tsurugizawa T, Ogiue-Ikeda M, Murakami G, Hojo Y, Ishii H, Kimoto T, Kawato S: Local neurosteroid production in the hippocampus: influence on synaptic plasticity of memory. Neuroendocrinology. 2006;84(4):255-63. Epub 2006 Dec 1. [PubMed:17142999]
  6. Notch EG, Mayer GD: 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8. doi: 10.1016/j.aquatox.2009.01.001. Epub 2009 Jan 23. [PubMed:19237207]
  7. Bennink HJ: Reprint of Are all estrogens the same? Maturitas. 2008 Sep-Oct;61(1-2):195-201. [PubMed:19434891]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Xue Y, Moore LB, Orans J, Peng L, Bencharit S, Kliewer SA, Redinbo MR: Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition. Mol Endocrinol. 2007 May;21(5):1028-38. Epub 2007 Feb 27. [PubMed:17327420]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Androgen binding
Specific Function
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone...
Gene Name
SHBG
Uniprot ID
P04278
Uniprot Name
Sex hormone-binding globulin
Molecular Weight
43778.755 Da
References
  1. Hong H, Branham WS, Ng HW, Moland CL, Dial SL, Fang H, Perkins R, Sheehan D, Tong W: Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and alpha-fetoprotein. Toxicol Sci. 2015 Feb;143(2):333-48. doi: 10.1093/toxsci/kfu231. Epub 2014 Oct 27. [PubMed:25349334]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Wang B, Sanchez RI, Franklin RB, Evans DC, Huskey SE: The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12. Epub 2004 Aug 10. [PubMed:15304426]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
Inducer
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. doi: 10.1124/dmd.104.000794. Epub 2004 Aug 10. [PubMed:15304429]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
Curator comments
Estradiol trans-inhibits BSEP only after its secretion into bile canaliculi by Mrp2.
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Lee JM, Trauner M, Soroka CJ, Stieger B, Meier PJ, Boyer JL: Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology. 2000 Jan;118(1):163-72. [PubMed:10611165]
  2. Huang L, Smit JW, Meijer DK, Vore M: Mrp2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats. Hepatology. 2000 Jul;32(1):66-72. [PubMed:10869290]
  3. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ: Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000 Feb;118(2):422-30. [PubMed:10648470]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Virus receptor activity
Specific Function
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presenc...
Gene Name
SLC10A1
Uniprot ID
Q14973
Uniprot Name
Sodium/bile acid cotransporter
Molecular Weight
38118.64 Da
References
  1. Lee JM, Trauner M, Soroka CJ, Stieger B, Meier PJ, Boyer JL: Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology. 2000 Jan;118(1):163-72. [PubMed:10611165]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Kauffmann HM, Schrenk D: Sequence analysis and functional characterization of the 5'-flanking region of the rat multidrug resistance protein 2 (mrp2) gene. Biochem Biophys Res Commun. 1998 Apr 17;245(2):325-31. [PubMed:9571149]
  2. Trauner M, Arrese M, Soroka CJ, Ananthanarayanan M, Koeppel TA, Schlosser SF, Suchy FJ, Keppler D, Boyer JL: The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology. 1997 Jul;113(1):255-64. [PubMed:9207286]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Kim WY, Benet LZ: P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93. [PubMed:15290871]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 04:32